Welcome to our dedicated page for GBNH news (Ticker: GBNH), a resource for investors and traders seeking the latest updates and insights on GBNH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GBNH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GBNH's position in the market.
Greenbrook TMS Inc. (NASDAQ: GBNH) reported its Q1 2021 results with a 14% increase in revenue to $11.3 million compared to Q4 2020, despite a 1% decrease year-over-year. New patient starts rose 19% to 1,583 from Q1 2020. However, the company recorded a regional operating loss of $1.5 million, an improvement from a $2.1 million loss in Q4 2020. The launch of the Spravato® pilot program is expected to expand treatment options. Total TMS Centers increased to 128, while treatment volumes fell 4% due to seasonal factors and adverse weather.
Greenbrook TMS Inc. (NASDAQ: GBNH) announced a delay in pricing for its previously disclosed equity offering due to unfavorable market conditions. This offering is tied to a regulatory framework including a short form base PREP prospectus in Canada and a registration statement with the SEC. The company operates 128 treatment centers, providing over 620,000 TMS treatments to more than 17,000 patients. The amended Prospectus and Registration Statement are expected before the Offering can proceed.
Greenbrook TMS Inc. (NASDAQ: GBNH) has postponed its first quarter 2021 financial results release from May 12, 2021, to after market hours on May 14, 2021. A conference call will take place on May 17, 2021, at 10:00 a.m. ET to discuss these results. Operating 128 treatment centers, Greenbrook specializes in TMS therapy, a non-invasive treatment for Major Depressive Disorder, having delivered over 620,000 treatments to more than 17,000 patients.
Greenbrook TMS Inc. (NASDAQ: GBNH) released preliminary unaudited operational and financial results for Q1 2021. New patient starts rose by 11% sequentially, totaling 1,583, and consultations increased 52% compared to Q1 2020. Expected revenue is projected between $11.1 million and $11.4 million, reflecting a 12%-15% increase from Q4 2020 but a slight decline year-over-year. Treatment volumes decreased 4% but showed a 9% growth from Q1 2020. The company remains optimistic about future growth amidst challenges.
Greenbrook TMS Inc. (NASDAQ: GBNH) has announced an underwritten public offering of common shares in the U.S. and Canada. The offering, managed by Stifel, Canaccord Genuity, and BTIG, aims to support the development of new mental health service centers for Transcranial Magnetic Stimulation (TMS) treatment, funding potential acquisitions, and general corporate purposes. The final terms depend on market conditions. A preliminary prospectus has been filed with Canadian and U.S. regulatory authorities, detailing vital information for potential investors.
Greenbrook TMS Inc. (NASDAQ: GBNH) will announce its Q1 2021 financial results on May 12, 2021, after market hours. A conference call hosted by CEO Bill Leonard and CFO Erns Loubser will take place on May 13, 2021, at 10:00 a.m. ET to discuss these results. Loubser is returning to his role after a medical leave, succeeding Interim CFO Ed Cordell. Greenbrook operates 128 centers providing Transcranial Magnetic Stimulation (TMS) therapy for mental health disorders, having delivered over 560,000 TMS treatments to more than 15,000 patients.
Greenbrook TMS Inc. (NASDAQ: GBNH) reported its fourth quarter and year-end 2020 results, highlighting a 21% revenue growth to $43.1 million despite a $0.6 million operating loss due to a revenue provision from new credentialing processes. New patient starts rose by 33% to 5,445, with treatment volumes increasing 26% to 195,992. However, Q4 revenue fell 21% to $9.9 million. The company added 14 TMS Centers in 2020, totaling 125 Centers, while continuing to adapt its operations for growth.
Greenbrook TMS Inc. (GTMS) announced its common shares will begin trading on NASDAQ under the symbol GBNH starting March 16, 2021. This listing is expected to enhance company visibility, access to capital, and liquidity. Greenbrook operates 126 treatment centers providing Transcranial Magnetic Stimulation (TMS) therapy for Major Depressive Disorder, having delivered over 510,000 treatments to date. The announcement emphasizes the company's growth and strategic positioning within the mental health sector.